Introduction: Container Closure Systems for Injectable Steroids are a foundational part of injectable drug-product development, since the packaging system must […]
Container Closure Systems for Injectable Steroids Read More »
Introduction: Extractables and Leachables in Lyophilized Drug Products are important pharmaceutical quality considerations because chemical substances originating from packaging and
Extractables and Leachables in Lyophilized Drug Products Read More »
Introduction Converting a peptide active pharmaceutical ingredient (API) from the trifluoroacetate (TFA) form to an acetate salt is an important
Introduction A thorough Extractables and Leachables Assessment of a peptide prefilled syringe generates the empirical chemical data necessary to support
Case Study: Extractables and Leachables Assessment for a Peptide Prefilled Syringe Read More »
Introduction Conducting a comprehensive Nitrosamine Risk Assessment and Trace-Level NDSRI Testing program is an essential regulatory and quality requirement for
Introduction: TTC in Extractables and Leachables (E&L) provides an exposure-based approach for evaluating potential toxicological concerns from low-level chemical substances
Threshold of Toxicological Concern (TTC) in E&L Safety Assessment: A Technical Deep Dive Read More »
Introduction Research-grade peptides and Good Manufacturing Practice (GMP) peptides represent two distinct categories of materials because they are manufactured under
Is Research-Grade Peptide the Same as GMP Peptide? Read More »
Introduction Peptide drugs require specialized cold-chain infrastructure because their dynamic amino acid structures and chemically reactive side chains are highly
Why Do Peptide Drugs Require Cold-Chain Storage and Shipping? Read More »
Reducing the Peptide Cost of Goods for commercial therapeutic drugs requires a comprehensive optimization strategy that addresses high process mass
How Do You Reduce Cost of Goods for a Commercial Peptide Drug? Read More »
Introduction: Immunogenicity testing determines whether a biosimilar monoclonal antibody triggers an unwanted immune response, and regulators require this data to
